Disclosed are substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-one compounds, pharmaceutical compositions comprising at least one such4substituted5-(3,5-dimethylisoxazol- 4-yl)indoline-2-one compound processes for the preparation thereof,and the use thereof for inhibiting BET family of bromodomains and for treating disorders mediated thereby,such as certain cancers.